Intech Investment Management LLC Sells 459 Shares of TransMedics Group, Inc. $TMDX

Intech Investment Management LLC decreased its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 1.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 26,676 shares of the company’s stock after selling 459 shares during the quarter. Intech Investment Management LLC owned about 0.08% of TransMedics Group worth $1,795,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. OneDigital Investment Advisors LLC increased its position in shares of TransMedics Group by 52.6% during the first quarter. OneDigital Investment Advisors LLC now owns 5,989 shares of the company’s stock worth $403,000 after acquiring an additional 2,065 shares in the last quarter. Principal Financial Group Inc. boosted its holdings in TransMedics Group by 2.8% during the 1st quarter. Principal Financial Group Inc. now owns 198,427 shares of the company’s stock worth $13,350,000 after acquiring an additional 5,480 shares during the last quarter. Vontobel Holding Ltd. bought a new stake in shares of TransMedics Group in the 1st quarter worth $291,000. New York State Teachers Retirement System lifted its position in shares of TransMedics Group by 183.2% during the first quarter. New York State Teachers Retirement System now owns 21,949 shares of the company’s stock valued at $1,477,000 after purchasing an additional 14,200 shares in the last quarter. Finally, Sugar Maple Asset Management LLC bought a new stake in TransMedics Group in the 1st quarter worth about $740,000. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Price Performance

Shares of NASDAQ:TMDX opened at $119.15 on Wednesday. The stock has a market cap of $4.06 billion, a P/E ratio of 61.74 and a beta of 2.18. TransMedics Group, Inc. has a 12 month low of $55.00 and a 12 month high of $169.29. The company has a 50 day moving average of $115.82 and a 200 day moving average of $106.11. The company has a current ratio of 9.86, a quick ratio of 9.17 and a debt-to-equity ratio of 1.61.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.44. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The business’s revenue for the quarter was up 37.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.35 EPS. TransMedics Group has set its FY 2025 guidance at EPS. As a group, sell-side analysts forecast that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analyst Ratings Changes

A number of analysts recently commented on the company. Wall Street Zen downgraded TransMedics Group from a “buy” rating to a “hold” rating in a research report on Saturday, August 30th. Evercore ISI started coverage on shares of TransMedics Group in a research report on Tuesday. They set an “outperform” rating and a $155.00 target price for the company. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Monday, August 25th. Morgan Stanley raised their target price on TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a research report on Friday, August 1st. Finally, Oppenheimer boosted their target price on TransMedics Group from $130.00 to $150.00 and gave the company an “outperform” rating in a research note on Tuesday, June 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.40.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.